


Claims:

1. A compound of formula I



wherein

X is O, NH, N(C₁₋₄)alkyl, CO or CHOH,

Y is CH or N,

A and B are each hydrogen or together form a second bond between the carbon atoms to which they are attached,

R₁ is hydrogen or (C₁₋₄)alkyl,

R₂ is optionally substituted (C₁₋₈)alkyl, (C₃₋₇)cycloalkyl, (C₃₋₇)cycloalkyl(C₁₋₄)alkyl, aryl or heteroaryl,

R₃ is CH(R_e)CONR_aR_b or (CH₂)_nNR_cR_d,

n is 0, 1 or 2,

R_a, R_b, R_c and R_d, independently, are hydrogen or optionally substituted (C₁₋₈)alkyl, (C₃₋₇)cycloalkyl, (C₃₋₇)cycloalkyl(C₁₋₄)alkyl, (C₇₋₉)bicycloalkyl, 1-aza-(C₇₋₉)bicycloalkyl, aryl, aryl(C₁₋₄)alkyl, heteroaryl, heteroaryl(C₁₋₄)alkyl or heterocyclyl, or

R_a, R_b, R_c and R_d, together with the nitrogen to which they are attached, form an optionally substituted pyrrolidinyl, piperidino, morpholino or piperazinyl group,

R_e is (C₁₋₈)alkyl, (C₁₋₄)alkoxy(C₁₋₄)alkyl, (C₃₋₇)cycloalkyl or (C₃₋₇)cycloalkyl(C₁₋₄)alkyl, and

R₄, R₅, R₆, R₇, R₈ and R₉, independently, are hydrogen, (C₁₋₄)alkyl, (C₁₋₄)alkoxy, (C₁₋₄)alkyl-SO₂, cyano, nitro or halogen, in free base or acid addition salt form.

2. A compound of formula I according to claim 1 wherein

X is O, NH, N(C₁₋₄)alkyl, CO or CHOH,

- Y is CH or N,
 A and B are each hydrogen or together form a second bond between the carbon atoms to which they are attached,
 R₁ is hydrogen or (C₁₋₄)alkyl,
 R₂ is optionally substituted (C₁₋₈)alkyl, (C₃₋₇)cycloalkyl, (C₃₋₇)cycloalkyl(C₁₋₄)alkyl, aryl or heteroaryl,
 R₃ is CH(R_e)CONR_aR_b or (CH₂)_nNR_cR_d,
 n is 0, 1 or 2,
 R_a, R_b, R_c and R_d, independently, are hydrogen or optionally substituted (C₁₋₈)alkyl, (C₃₋₇)cycloalkyl, (C₃₋₇)cycloalkyl(C₁₋₄)alkyl, aryl, aryl(C₁₋₄)alkyl, heteroaryl or heteroaryl(C₁₋₄)alkyl or
 R_a, R_b, R_c and R_d, together with the nitrogen to which they are attached, form an optionally substituted pyrrolidinyl, piperidino, morpholino or piperazinyl group,
 R_e is (C₁₋₈)alkyl, (C₁₋₄)alkoxy(C₁₋₄)alkyl, (C₃₋₇)cycloalkyl or (C₃₋₇)cycloalkyl(C₁₋₄)alkyl, and
 R₄, R₅, R₆, R₇, R₈ and R₉, independently, are hydrogen, (C₁₋₄)alkyl, (C₁₋₄)alkoxy, (C₁₋₄)alkyl-SO₂, cyano, nitro or halogen, in free base or acid addition salt form.

3. A compound of formula I according to claim 1 wherein

- X is O, NH or CO,
 Y is CH or N,
 A and B are each hydrogen or together form a second bond between the carbon atoms to which they are attached,
 R₁ is hydrogen,
 R₂ is (C₁₋₄)alkyl, or phenyl, which is unsubstituted or substituted by hydroxy, amino or halogen,
 R₃ is CH(R_e)CONR_aR_b or (CH₂)_nNR_cR_d,
 n is 0 or 1,
 R_a and R_b, independently, are hydrogen, (C₁₋₇)alkyl, (C₁₋₄)alkoxy(C₁₋₄)alkyl, benzyl, phenyl, (C₃₋₅)cycloalkyl(C₁₋₄)alkyl, pyridyl, pyridyl(C₁₋₄)alkyl, (C₁₋₄)alkyl piperidinyl, tetrahydropyranyl, (C₇₋₈)bicycloalkyl, 1-aza-(C₇₋₈)bicycloalkyl; (C₅₋₈)cycloalkyl substituted by hydroxy; or pyrazolyl or isoxazolyl being unsubstituted or substituted by (C₁₋₄)alkyl;


- 44 -

R_c and R_d , independently, are hydrogen, tetrahydronaphthyl, (C_{1-4}) alkoxy tetrahydronaphthyl, (C_{3-5}) cycloalkyl being unsubstituted or substituted by halophenyl; chromanyl being substituted by halogen, (C_{1-4}) alkyl or (C_{3-7}) cycloalkyl; or (C_{1-4}) alkyl being unsubstituted or mono or disubstituted by (C_{5-7}) cycloalkyl, phenyl, (C_{1-4}) alkoxy phenyl, di (C_{1-4}) alkoxy phenyl, halophenyl, phenoxy phenyl, (C_{1-4}) alkyl phenyl, hydroxy (C_{1-4}) alkyl phenyl, (C_{1-4}) alkoxy (C_{1-4}) alkoxy phenyl, naphthyl, pyridyl, thiadiazolyl, benzimidazolyl or furyl;

R_e is (C_{1-8}) alkyl, and


R_4 , R_5 , R_6 , R_7 , R_8 and R_9 , independently, are hydrogen or halogen, in free base or acid addition salt form.

4. A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, which includes the steps of acylating a compound of formula II



II

wherein R_1 , R_2 and R_3 are as defined in claim 1, with an acid of formula III



III

wherein X, Y, A, B, R_4 , R_5 , R_6 , R_7 , R_8 and R_9 are as defined in claim 1, or an activated form thereof, and recovering the so obtained compound of formula I in free base or acid addition salt form.

5. A compound of any one of claims 1 to 3 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.

6. A compound of any one of claims 1 to 3 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation.
7. A pharmaceutical composition comprising a compound of any one of claims 1 to 3 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.
8. The use of a compound of any one of claims 1 to 3 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical, for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation.
9. The use of a compound of any one of claims 1 to 3 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation.
10. A method for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of any one of claims 1 to 3 in free base or pharmaceutically acceptable acid addition salt form.
11. A combination comprising a therapeutically effective amount of a compound of any one of claims 1 to 3 in free base or pharmaceutically acceptable acid addition salt form and a second drug substance, for simultaneous or sequential administration.